



# TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

29.06.2021

To,

**BSE Limited**

PhirozeJeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

**Dear Sir/Madam,**

**Scrip Code: 539428**

**Sub: Submission of Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended on 31<sup>st</sup> March, 2021**

Please find the enclosed herewith Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended on 31<sup>st</sup> March, 2021 along with Auditors Report thereon approved by the Board of Directors of the Company at its Meeting held on Tuesday, 29th June, 2021 at A 601, Floor No.6, Kailash Business Park, Veer Savarkar Marg, Vikroli - West, Mumbai – 400079 at 1.00 p.m., in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you.

**For Tejnaksh Healthcare Limited**

**Dr. Ashish V. Rawandale**

**Managing Director**

**DIN:- 02005733**





# TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

29.06.2021

To,

**BSE Limited**

PhirozeJeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

Dear Sir/Madam,

**Scrip Code: 539428**

**Sub: Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements)Regulation, 2015, in respect of Audit Report for the year ended March 31,2021.**

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, as amended vide SEBI Circular CIR/CFD/CMD/56/2016 dated May 27, 2016, we do hereby confirm that the Statutory Auditors of the Company M/s. P. D. Dalal & Co., Chartered Accountants, have issued an Audit Report with unmodified Opinion on Annual Audited (Standalone and Consolidated) Financial Results for the year ended on March 31, 2021.

This is for your information and record.

Thanking you.

For Tejnaksh Healthcare Limited

**Dr. Ashish V. Rawandale**

**Managing Director**

**DIN:- 02005733**





**Independent Auditor's Report on Audited Standalone Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors of  
Tejnaksh Healthcare Limited,  
Mumbai

**Report on the audit of the Standalone Financial Statements**

**Opinion**

We have audited the accompanying standalone quarterly and year to date standalone financial results of **M/s. Tejnaksh Healthcare Limited** ("the Company") which includes joint operations for the quarter and year ended March 31, 2021 (the "Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other financial information for the quarter and year ended March 31<sup>st</sup> 2021.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.





**Management's Responsibility for the Standalone Financial Statements**

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance "with Regulations 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance "with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities: selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

**Auditor's Responsibility for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.





# P.D.DALAL & Co. <sup>Regd.</sup>

**Chartered Accountants**

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## Other Matters

The Statement includes the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2021 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For and on behalf of

**P.D.Dalal & Co.**

*Chartered Accountants*

Firm Registration No.102047W

*Aashish S. Kakaria*

(Aashish S. Kakaria)

Partner

Membership No.102915

UDIN :21102915AAAAEJ9573



Mumbai

29<sup>th</sup> June, 2021



# TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

## STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED MARCH, 2021

(Rs in 'Lakhs)

Sl.No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2021	December 31, 2020	March 31, 2020	March 31, 2021	March 31, 2020
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>1</b>	<b>REVENUE</b>					
(a)	Revenue from operations (net)	218.66	249.85	232.45	855.81	1,113.77
(b)	Other income	11.06	0.85	22.10	15.35	84.38
	<b>Total Revenue (I)</b>	<b>229.71</b>	<b>250.72</b>	<b>254.55</b>	<b>871.15</b>	<b>1,198.15</b>
<b>2</b>	<b>EXPENSES</b>					
(a)	Purchases of stock-in-trade	25.98	7.64	7.61	52.67	53.04
(b)	Changes in inventories of Stock-in-Trade	(0.53)	3.64	14.10	(8.07)	12.85
(c)	Employee benefits expense	19.86	27.66	44.82	91.53	163.80
(d)	Finance costs	12.00	12.09	24.50	53.63	79.52
(e)	Depreciation and amortization expense	14.65	15.85	15.40	61.19	58.59
(f)	Other expenses	77.75	116.10	145.03	361.19	564.28
	<b>Total Expenses (II)</b>	<b>149.71</b>	<b>182.98</b>	<b>251.47</b>	<b>612.14</b>	<b>932.09</b>
<b>3</b>	<b>Profit before tax (I) - (II)</b>	<b>80.00</b>	<b>67.75</b>	<b>3.08</b>	<b>259.01</b>	<b>266.06</b>
<b>4</b>	<b>Tax expense:</b>					
(a)	Current tax	20.65	11.55	4.34	57.27	61.38
(b)	Deferred tax	(0.16)	(4.41)	6.47	1.32	12.32
	<b>Total Tax Expenses</b>	<b>20.49</b>	<b>7.14</b>	<b>10.82</b>	<b>58.59</b>	<b>73.70</b>
<b>5</b>	<b>Profit for the Period</b>	<b>59.51</b>	<b>60.61</b>	<b>(7.74)</b>	<b>200.42</b>	<b>192.36</b>
<b>6</b>	<b>OTHER COMPREHENSIVE INCOME</b>					
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:					
	Actuarial gain / (loss) on liabilities	1.32	-	-	1.32	-
	Income tax effect	(0.33)	-	-	(0.33)	-
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	-	-
	<b>Other Comprehensive income for the period, net of tax</b>	<b>0.99</b>	<b>-</b>	<b>-</b>	<b>0.99</b>	<b>-</b>
	<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX</b>	<b>60.49</b>	<b>60.61</b>	<b>(7.74)</b>	<b>201.40</b>	<b>192.36</b>
<b>7</b>	<b>Paid up Equity Share Capital (Face value Rs 10/- each.)</b>	<b>101.57</b>	<b>101.57</b>	<b>101.57</b>	<b>101.57</b>	<b>101.57</b>
<b>8</b>	<b>Basic and Diluted earnings per share (INR)</b>	<b>0.59</b>	<b>0.60</b>	<b>(0.08)</b>	<b>1.97</b>	<b>1.89</b>







# TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

## AUDITED STANDALONE BALANCE SHEET AS AT 31st MARCH, 2021

Particulars	Amount Rs.Lacs	
	March 31, 2021	March 31, 2020
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
(a) Property, Plant and Equipment	1,082.38	1,205.35
(b) Capital work-in-progress	3.90	3.15
(c) Goodwill	350.00	450.00
(d) Other Intangible Assets	1.21	3.79
(e) Intangible Assets Under Development	75.13	62.13
(f) Financial Assets		
(i) Investments	106.01	106.01
(ii) Other Financial Assets	505.96	1.41
(g) Other Non-Current Assets	49.12	21.40
	<b>2,173.70</b>	<b>1,853.24</b>
<b>Current assets</b>		
(a) Inventories	41.53	33.46
(b) Financial Assets	-	
(i) Trade Receivables	36.76	52.99
(ii) Cash and Cash Equivalents	56.20	102.96
(iii) Other Financial Assets	11.16	11.16
(c) Other Current Assets	67.93	349.41
(d) Current tax Asset	-	25.19
	<b>213.59</b>	<b>575.17</b>
<b>TOTAL</b>	<b>2,387.29</b>	<b>2,428.41</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital	1,015.68	1,015.68
(b) Other Equity	686.88	485.48
	<b>1,702.56</b>	<b>1,501.16</b>
<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	418.22	659.34
(ii) Other financial liabilities	38.07	34.65
(b) Deferred Tax liabilities (Net)	72.75	71.10
(c) Other Non Current Liabilities	6.35	6.35
(d) Non Current Provision	10.81	10.22
	<b>546.20</b>	<b>781.66</b>
<b>Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	4.13	6.36
(ii) Trade Payables		
Micro and Small Enterprises	-	-
Others	15.94	26.21
(iii) Other financial liabilities	81.17	90.59
(b) Other Current Liabilities	10.51	20.00
(c) Current Provision	2.82	2.44
(d) Current tax Liability	23.96	-
	<b>138.53</b>	<b>145.60</b>
<b>TOTAL</b>	<b>2,387.29</b>	<b>2,428.41</b>





# TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

## AUDITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2021

Particulars	Amount Rs. Lacs	
	March 31, 2021 (Audited)	March 31, 2020 (Audited)
<b>Profit before tax</b>	<b>259.01</b>	<b>266.06</b>
<b>Adjustments for:</b>		
Depreciation and amortisation expense	61.19	58.59
Interest Income	(5.58)	(9.00)
Finance costs	53.63	79.52
(Profit)/loss on sale/disposal property, plant and equipment and Intangibles	0.56	-
Bad Debts	4.30	-
Provision for Gratuity	2.28	9.66
<b>Change in operating assets and liabilities:</b>		
(Increase)/Decrease in trade receivables	11.93	(30.89)
(Increase)/Decrease in inventories	(8.07)	12.85
Increase/(decrease) in trade payables	(10.27)	(5.37)
(Increase) in other financial assets	(504.55)	(0.10)
(Increase)/decrease in other assets	196.49	(233.14)
Increase/(decrease) in other financial liabilities	(16.93)	41.45
Increase/(decrease) in other liabilities	(9.49)	(59.79)
<b>Cash generated from operations</b>	<b>34.50</b>	<b>129.86</b>
Less: Income taxes paid/(refund)	49.15	(29.69)
<b>Net cash inflow from operating activities</b>	<b>83.65</b>	<b>100.17</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Payments for property, plant and equipment and Intangibles	(44.34)	(102.02)
Proceeds from disposal of property, plant and equipment and Intangibles	207.40	-
Intangible asset under development	(13.00)	(22.75)
Interest received	5.58	9.00
<b>Net cash outflow from investing activities</b>	<b>155.64</b>	<b>(115.77)</b>







# TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from non current borrowings	-	150.02
Repayment of non current borrowings	(231.83)	(47.12)
Proceeds from current borrowings	7.55	6.36
Repayment of current borrowings	(9.77)	(17.67)
Interest paid	(52.00)	(69.67)
Acquisition of non-controlling interests	-	-
<b>Net cash inflow (outflow) from financing activities</b>	<b>(286.05)</b>	<b>21.91</b>
Net increase (decrease) in cash and cash equivalents	(46.77)	6.32
Cash and Cash Equivalents at the beginning of the financial year	102.96	96.65
<b>Cash and Cash Equivalents at end of the year</b>	<b>56.20</b>	<b>102.96</b>
Reconciliation of cash and cash equivalents as per the cash flow statement:		
Cash and cash equivalents as per above comprise of the following:		
Balances with banks in current accounts	21.70	31.62
Cash on hand	34.49	71.34
<b>Balances per statement of cash flows</b>	<b>56.20</b>	<b>102.96</b>

## Notes:

1. The Audit Committee has reviewed, and the Board of Directors has approved the above results and its release at their respective meetings held on 29th June, 2021.

2. The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.

The figures for quarter ended March 31, 2021 are balancing figures between the audited figures of the full financial year and the reviewed year-to-date figures upto the third quarter of the financial year.

3. The Company's operating segment is 'Medical and Healthcare Services. Since the Company has a single operating segment, disclosure pertaining to segments as per Regulation 33(1)(c) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.





# TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

4. The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company's operations and revenue during the period were impacted due to COVID-19. The Company has taken into account the possible impact of COVID-19 in preparation of the audited standalone financial results, including its assessment of recoverable value of its assets based on internal and external information upto the date of approval of these audited standalone financial results and current indicators of future economic conditions.

For and on behalf of board of Directors

Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)

Managing Director

DIN: 02005733

June 29, 2021





**Independent Auditor's Report on Audited Consolidated Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors of  
Tejnaksh Healthcare Limited,  
Mumbai

**Report on the audit of the Consolidated Financial Statements**

**Opinion**

We have audited the accompanying standalone quarterly and year to date consolidated financial results of **M/s. Tejnaksh Healthcare Limited** which includes joint operations (The Company), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and year ended March 31, 2021 (the "Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of our report on the separate financial statement/ financial information of subsidiary, the Statement:

- i. Includes the results of the following entity: **TejVedaant Healthcare Private Limited (Subsidiary).**
- ii. Is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- iii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of consolidated net profit and other financial information for the quarter and year ended March 31<sup>st</sup> 2021.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled





our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

### **Management's Responsibility for the Standalone Financial Statements**


The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other financial information of the Group in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with the Listing Regulations. The respective Board of Directors of the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the company included in the Group are responsible for assessing the ability of the Group Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the company included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibility for the Audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.






As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to





communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

**Other Matters**

1. The accompanying Statement includes the audited financial results/statements and other financial information, in respect of

TejVedaant Healthcare Private Limited (Subsidiary), whose financial results/statements reflect total assets of Rs 233.85 Lacs as at March 31, 2021, total revenues of 194.77 lacs and 390.24 lacs, total net profit after tax of Rs 26.12 lacs and Rs 6.50 lacs, total comprehensive income of Rs 26.20 lacs and Rs 6.58 lacs for the quarter and year ended on that date respectively, and net cash outflows of Rs 40.66 lacs for the year ended March 31, 2021, as considered in the Statement which have been audited by us.

The Statement includes the results for the quarter ended March 31, 2021 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2021 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For and on behalf of

**P.D.Dalal & Co.**

Chartered Accountants

Firm Registration No. 102047W

*Aashish S. Kakaria*

(Aashish S. Kakaria)

Partner

Membership No. 102915

UDIN : 21102915AAAAEK2259



Mumbai

29<sup>th</sup> June, 2021





# TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

## STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED MARCH, 2021

(Rs in 'Lakhs)

Sl.No.	Particulars	Quarter Ended			Year Ended	
		March 31,2021	December 31,2020	March 31,2020	March 31,2021	March 31,2020
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	<b>REVENUE</b>					
(a)	Revenue from operations (net)	361.08	342.16	354.69	1,196.01	1,675.65
(b)	Other income	11.87	0.01	15.86	13.85	70.11
	<b>Total Revenue (I)</b>	<b>372.95</b>	<b>342.17</b>	<b>370.55</b>	<b>1,209.86</b>	<b>1,745.76</b>
2	<b>EXPENSES</b>					
(a)	Purchases of stock-in-trade	38.44	21.50	15.75	95.67	109.75
(b)	Changes in inventories of Stock-in-Trade	0.54	6.31	15.57	(6.17)	19.97
(c)	Employee benefits expense	37.59	40.22	67.21	138.75	255.42
(d)	Finance costs	11.15	11.24	19.79	50.21	76.10
(e)	Depreciation and amortization expense	16.36	17.56	17.16	68.05	65.44
(f)	Other expenses	161.55	177.06	228.00	596.53	922.51
	<b>Total Expenses (II)</b>	<b>265.64</b>	<b>273.89</b>	<b>363.48</b>	<b>943.05</b>	<b>1,449.19</b>
3	<b>Profit before tax (I) - (II)</b>	<b>107.30</b>	<b>68.28</b>	<b>7.07</b>	<b>266.80</b>	<b>296.57</b>
4	<b>Tax expense:</b>					
(a)	Current tax	22.53	11.55	5.75	58.15	69.30
(b)	Deferred tax	(0.31)	(4.75)	6.33	0.73	12.69
	<b>Total Tax Expenses</b>	<b>22.22</b>	<b>6.80</b>	<b>12.08</b>	<b>59.88</b>	<b>81.99</b>
5	<b>Profit for the year</b>	<b>85.08</b>	<b>61.48</b>	<b>(5.01)</b>	<b>206.92</b>	<b>214.58</b>
6	<b>OTHER COMPREHENSIVE INCOME</b>					
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:					
	Actuarial gain / (loss) on liabilities	1.42	-	-	1.42	-
	Income tax effect	(0.36)	-	-	(0.36)	-
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	-	-
	Other Comprehensive income for the year, net of tax	1.06	-	-	1.06	-
	<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX</b>	<b>86.15</b>	<b>61.48</b>	<b>(5.01)</b>	<b>207.99</b>	<b>214.58</b>
7	<b>Profit for the year attributable to:</b>					
	Equity holders of the parent	79.10	61.26	(5.69)	205.30	209.01
	Non-controlling interests	6.53	0.22	0.68	1.63	5.55
8	<b>Total comprehensive income for the year attributable to:</b>					
	Equity holders of the parent	1.04	-	-	1.04	-
	Non-controlling interests	0.02	-	-	0.02	-
9	<b>Total comprehensive income for the year attributable to:</b>					
	Equity holders of the parent	80.14	61.26	(5.69)	206.34	209.01
	Non-controlling interests	6.55	0.22	0.68	1.65	5.55
10	<b>Paid up Equity Share Capital (Face value Rs 100/- each.)</b>	<b>101.57</b>	<b>101.57</b>	<b>101.57</b>	<b>101.57</b>	<b>101.57</b>
11	<b>Basic and Diluted earnings per share (INR)</b>	<b>0.78</b>	<b>0.60</b>	<b>(0.06)</b>	<b>2.02</b>	<b>2.06</b>





# TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

## AUDITED CONSOLIDATED BALANCE SHEET AS AT 31st MARCH, 2021

Particulars	Amount Rs.Lacs	
	March 31, 2021	March 31, 2020
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
(a) Property, Plant and Equipment	1,152.93	1,282.77
(b) Capital work-in-progress	3.90	3.15
(c) Goodwill	350.00	450.00
(d) Other Intangible Assets	1.21	3.79
(e) Intangible Assets Under Development	75.13	62.13
(f) Financial Assets		
(i) Investments	0.01	0.01
(ii) Other Financial Assets	505.96	1.41
(g) Other Non-Current Assets	46.58	30.42
	<b>2,135.71</b>	<b>1,833.67</b>
<b>Current assets</b>		
(a) Inventories	69.69	63.52
(b) Financial Assets		
(i) Trade Receivables	46.56	52.68
(ii) Cash and Cash Equivalents	123.30	129.40
(iii) Other Financial Assets	12.87	12.51
(c) Other Current Assets	69.07	354.00
(d) Current tax Asset	-	45.11
	<b>321.48</b>	<b>657.22</b>
<b>TOTAL</b>	<b>2,457.19</b>	<b>2,490.90</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital	1,015.68	1,015.68
(b) Other Equity	715.76	509.42
<b>Equity attributable to equity holders of the parent</b>		
Non Controlling Interest	44.96	43.31
<b>Total Equity</b>	<b>1,776.40</b>	<b>1,568.41</b>
<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
(a) Financial Liabilities		
Borrowings	418.22	659.34
(b) Deferred Tax liabilities (Net)	75.68	74.60
(c) Non Current Provision	17.29	14.31
	<b>511.18</b>	<b>748.25</b>
<b>Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	0.40	-
(ii) Trade Payables		
Micro and Small Enterprises	-	-
Others	46.64	54.31
(iii) Other financial liabilities	89.04	99.90
(b) Other Current Liabilities	5.13	17.57
(c) Current Provision	2.55	2.46
(d) Current tax Liability	25.84	-
	<b>169.61</b>	<b>174.24</b>
<b>TOTAL</b>	<b>2,457.19</b>	<b>2,490.90</b>







# TEJNAKSH HEALTHCARE LIMITED


Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

## AUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2021

Particulars	Amount Rs.Lacs	
	March 31, 2021	March 31, 2020
<b>Profit before tax</b>	<b>266.80</b>	<b>296.55</b>
<b>Adjustments for:</b>		
Depreciation and amortisation expense	68.05	65.44
Interest Income	(5.58)	(9.67)
Finance costs	50.21	76.10
(Profit)/loss on sale/disposal property, plant and equipment and Intangibles	0.56	-
Bad Debts	4.30	-
Provision for Gratuity	4.50	13.76
<b>Change in operating assets and liabilities:</b>		
(Increase)/Decrease in trade receivables	1.82	(33.66)
(Increase)/Decrease in inventories	(6.17)	19.97
Increase/(decrease) in trade payables	(7.67)	(5.27)
(Increase) in other financial assets	(515.84)	24.27
(Increase)/decrease in other assets	209.63	(228.42)
Increase/(decrease) in other financial liabilities	(10.86)	12.94
Increase/(decrease) in other liabilities	(12.45)	(67.10)
<b>Cash generated from operations</b>	<b>47.31</b>	<b>164.92</b>
Less: Income taxes paid/(refund)	70.96	(48.78)
<b>Net cash inflow from operating activities</b>	<b>118.27</b>	<b>116.14</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Payments for property, plant and equipment and Intangibles	(44.34)	(107.90)
Proceeds from disposal of property, plant and equipment and Intangibles	207.40	-
Intangible asset under development	(13.00)	(22.75)
Interest received	5.58	9.67
<b>Net cash outflow from investing activities</b>	<b>155.64</b>	<b>(120.98)</b>





# TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from non current borrowings	-	150.02
Repayment of non current borrowings	(231.83)	(47.12)
Proceeds from current borrowings	-	-
Repayment of current borrowings	0.40	(17.67)
Interest paid	(48.58)	(74.98)
Acquisition of non-controlling interests	-	-
<b>Net cash inflow (outflow) from financing activities</b>	<b>(280.01)</b>	<b>10.24</b>
Net increase (decrease) in cash and cash equivalents	(6.10)	5.40
Cash and Cash Equivalents at the beginning of the financial year	129.40	124.00
<b>Cash and Cash Equivalents at end of the year</b>	<b>123.30</b>	<b>129.40</b>
Reconciliation of cash and cash equivalents as per the cash flow statement:		
Cash and cash equivalents as per above comprise of the following:		
Balances with banks in current accounts	74.85	50.35
Cash on hand	48.45	79.05
<b>Balances per statement of cash flows</b>	<b>123.30</b>	<b>129.40</b>

## Notes:

1. The Audit Committee has reviewed, and the Board of Directors has approved the above results and its release at their respective meetings held on 29th June, 2021.
2. The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.

The figures for quarter ended March 31, 2021 are balancing figures between the audited figures of the full financial year and the reviewed year-to-date figures upto the third quarter of the financial year.

3. The Group's operating segment is 'Medical and Healthcare Services. Since the Group has a single operating segment, disclosure pertaining to segments as per Regulation 33(1)(c) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.







# TEJNAKSH HEALTHCARE LIMITED

Regd. Add.: A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

4. The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Group's operations and revenue during the period were impacted due to COVID-19. The Group has taken into account the possible impact of COVID-19 in preparation of the audited standalone financial results, including its assessment of recoverable value of its assets based on internal and external information upto the date of approval of these audited standalone financial results and current indicators of future economic conditions.

For and on behalf of board of Directors

Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)

Managing Director

DIN: 02005733

June 29, 2021

